Prevalence of RAS oncogene mutation in head and neck carcinomas.
about
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.Molecular Aspects of Head and Neck Cancer TherapyHRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptorsPrognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.Prognostic significance of methyl-p-hydroxy-phenyllactate-esterase activity in laryngeal squamous cell carcinomaThe molecular pathogenesis of head and neck squamous cell carcinomaPlatinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistancePIK3CA mutations in head and neck squamous cell carcinoma.Prevalence of K-RAS Codons 12 and 13 Mutations in Locally Advanced Head and Neck Squamous Cell Carcinoma and Impact on Clinical Outcomes
P2860
Q27851592-64EBEA8A-6202-4C43-978E-CB0A5EE49681Q28082815-FB846D10-DA82-473F-98E6-FA9825FAF9E7Q33568344-060E7D47-99E8-45A7-8050-5248880BA6ABQ34321100-0096B0D4-8AE4-4E3A-AE2F-FBD790296FA9Q35979236-9AC4D2EC-EF40-48A7-9662-D8F4E5AE887CQ36138893-C1BF9DF6-AEAB-4595-ACEE-B6390681DD06Q36292410-152722E6-9C1C-44CB-AD55-229EF5F80CF9Q36659339-7DC10D05-C79A-45EB-9290-080A71CD0DF0Q36801922-C081CED9-3239-4DB7-AEA1-267C666DFDEFQ38118934-87FDB533-FAF0-4F0F-9DEF-0FE7A2DF2A57Q40305620-4893B4B3-F1F5-45F6-994B-8F0EFBF60BA0Q40811967-E2FDA2BE-1529-4CEF-BFD4-16D362F64D0B
P2860
Prevalence of RAS oncogene mutation in head and neck carcinomas.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Prevalence of RAS oncogene mutation in head and neck carcinomas.
@en
type
label
Prevalence of RAS oncogene mutation in head and neck carcinomas.
@en
prefLabel
Prevalence of RAS oncogene mutation in head and neck carcinomas.
@en
P2093
P1476
Prevalence of RAS oncogene mutation in head and neck carcinomas.
@en
P2093
P304
P577
1992-10-01T00:00:00Z